Low-solubility and poorly bioavailable compounds pose persistent challenges in pharmaceutical pipelines. This webinar delves into Lonza's ‘right first time’ strategy, utilizing material-sparing and time-saving methods to swiftly advance molecules from development to commercialization.

Key aspects include:

  • Feasibility screening to determine the optimal manufacturing approach between spray drying (SD) and hot melt extrusion (HME).
  • Lonza’s innovative approach to screening HMEs, specifically at a milligram scale, to better capture the physical process of extrusion.
  • Progression in amorphous solid dispersion (ASD) development from drug product intermediate to the final product, emphasizing material-sparing tools for formulation selection and scale-up.

The second part of the webinar focuses on efficient practices in ASD-based tablet feasibility and demonstration batches. It explores:

  • Understanding key differences between spray drying and hot melt extrusion through feasibility screening.
  • Material-sparing uses of a compaction simulator to inform tablet development.
  • The significance of material-sparing techniques in saving time and costs during the scaling process.


By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center